Aclaris Therapeutics, Inc. (ACRS) financial statements (2020 and earlier)

Company profile

Business Address 640 LEE ROAD
WAYNE, PA 19087
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:7516820917492
Cash and cash equivalents  203010
Short-term investments3911117410775
Other undisclosed cash, cash equivalents, and short-term investments365715377
Receivables150  
Inventory, net of allowances, customer advances and progress billings 1   
Inventory 1   
Deferred costs   0 
Disposal group, including discontinued operation5    
Assets held-for-sale, not part of disposal group    0
Other undisclosed current assets36(9)(36)(6)
Total current assets:8417920013987
Noncurrent Assets
Property, plant and equipment24200
Long-term investments and receivables  15377
Long-term investments  15377
Intangible assets, net (including goodwill)79126  
Goodwill 1919  
Intangible assets, net (excluding goodwill)7737  
Other noncurrent assets50000
Other undisclosed noncurrent assets   0 
Total noncurrent assets:149643388
TOTAL ASSETS:9827624417694
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities18271362
Accounts payable1015831
Accrued liabilities813531
Disposal group, including discontinued operation4    
Other liabilities1    
Total current liabilities:22271362
Noncurrent Liabilities
Liabilities, other than long-term debt635  
Deferred tax liabilities, net11  
Deferred income tax liabilities1
Other liabilities421  
Business combination, contingent consideration, liability214  
Other undisclosed noncurrent liabilities 30 0 
Total noncurrent liabilities:63350 
Total liabilities:28601872
Stockholders' equity
Stockholders' equity attributable to parent7021522516993
Additional paid in capital524507385261136
Accumulated other comprehensive loss(0)(0)(0)(0)(0)
Accumulated deficit(454)(292)(159)(91)(43)
Total stockholders' equity:7021522516993
TOTAL LIABILITIES AND EQUITY:9827624417694

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues4102  
Revenue, net2  
Cost of revenue(4)(7)(1)  
Gross profit:030  
Operating expenses(111)(139)(73)(49)(21)
Operating loss:(111)(135)(72)(49)(21)
Nonoperating income (expense)(2)3200
Investment income, nonoperating    0
Other nonoperating income (expense)(2)320 
Interest and debt expense(0)    
Loss from continuing operations before equity method investments, income taxes:(114)(133)(70)(48)(21)
Other undisclosed loss from continuing operations before income taxes(48)    
Loss from continuing operations before income taxes:(161)(133)(70)(48)(21)
Income tax benefit  2  
Net loss attributable to parent:(161)(133)(69)(48)(21)
Preferred stock dividends and other adjustments    (3)
Net loss available to common stockholders, diluted:(161)(133)(69)(48)(23)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(161)(133)(69)(48)(21)
Other comprehensive income (loss)000(0)(0)
Comprehensive loss, net of tax, attributable to parent:(161)(133)(69)(48)(21)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: